- 3rd in the UK for Medicine – The Guardian University Guide 2018
- 2nd in the UK for Dentistry – The Guardian University Guide 2018
- 4th in UK for Medicine - The Complete University Guide 2018
- 1st in UK for Dentistry - The Complete University Guide 2018
More about rankings and league tables.
National Student Survey (NSS) results – 2017
- 92 per cent overall student satisfaction
- Ranked 1st in London
- 93 per cent of medical students were satisfied with the teaching on their course
- Ranked top 5 in the UK for assessment and feedback, and organisation and management
Russell Group Member
Queen Mary University of London (QMUL) is one of 24 leading UK universities represented by the Russell Group that are committed to maintaining the very best research, an outstanding teaching and learning experience, excellent graduate employability and unrivalled links with business and the public sector.
Barts and The London School of Medicine and Dentistry is a faculty of QMUL. One of the leading medical schools in the UK, Barts and The London School of Medicine and Dentistry brings together two venerable teaching institutions: St Bartholomew's Hospital, which dates back to 1123, and The London Hospital Medical College, which was the first medical school in England and Wales, founded in 1785.
This wealth of tradition is combined with some of the most modern medical facilities in the UK, including the largest new hospital in Europe, the first new dental hospital building in the UK for 40 years, and in the Blizard Building, some of the largest open-plan biomedical research laboratories in Europe.
As you would expect from a medical college that has 230 years experience of training the next generation of doctors and surgeons, our students are very satisfied with their learning experience – in the most recent National Student Survey (NSS 2014), 96 per cent were satisfied with the quality of their course. We will bringing the same standards of innovative research-led teaching and investment in excellent facilities to our MBBS in Malta.
Through partnership with our linked trusts, notably Barts Health NHS Trust, and our associated University Hospital Trusts – Homerton, Newham, Whipps Cross and Queen’s (Romford) the School’s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.
According to the Research Excellence Framework (REF 2014) Barts and The London School of Medicine and Dentistry is placed within the top seven UK institutions in all three Units of Assessment – Clinical Medicine; Public Health, Health Services and Primary Care; and Allied Health Professions, Dentistry, Nursing and Pharmacy.
Research is focused on translational research, cancer, cardiac, dentistry, inflammation, endocrinology/ metabolism, immunology and infectious diseases, genomics, neuroscience, gastroenterology, epidemiology and primary care.
The School is nationally and internationally recognised for research in these areas, reflected in the £40 million it attracts annually in research income. Its fundamental mission, with its partner NHS Trusts, and other partner organisations, such as CR-UK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research.
School of Medicine and Dentistry
Strategy - the next five years
Our aim for the next five years is to grow and to further improve our research, teaching and training excellence, impacting on local, national and international communities. We will contribute and enhance the success of QMUL as a vibrant Russell Group University.
To access the five-year strategy please visit the website.
The School is organised into the following Institutes:
- Barts Cancer Institute
- Blizard Institute of Cell and Molecular Science
- Institute of Health Sciences Education
- Institute of Dentistry
- William Harvey Research Institute
- Wolfson Institute of Preventive Medicine
More about our institutes
The School is also home to the first Cancer Research UK Clinical Centre to be established which takes an innovative 'molecules to patient' approach to research.